Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713212 | 0.89 | TP53 (0.47) | GPR119DPP4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12713228 | 0.85 | GPR119 (0.51) | GPR119DPP4ALDH1A1LMNACYP3A4 | |
| SCHEMBL12713229 | 0.84 | GPR119 (0.50) | GPR119DPP4ALDH1A1LMNACYP3A4 | |
| SCHEMBL12713231 | 0.83 | GPR119 (0.49) | GPR119DPP4ALDH1A1LMNACYP3A4 | |
| SCHEMBL14435978 | 0.82 | GPR119 (0.52) | GPR119DPP4ALDH1A1LMNACYP3A4 | |
| SCHEMBL2338827 | 0.82 | GPR119 (0.52) | GPR119DPP4ALDH1A1LMNACYP3A4 | |
| SCHEMBL14436421 | 0.77 | PDK4 (0.47) | GPR119 | |
| SCHEMBL12713226 | 0.77 | PDK4 (0.47) | GPR119 | |
| SCHEMBL20438978 | 0.77 | SMN1; SMN2 (0.59) | GPR119ALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL14401276 | 0.77 | SMN1; SMN2 (0.47) | GPR119ALDH1A1LMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2004604-B1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2007115798-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | GPR119 7/4885DPP4 71/4885ALDH1A1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.